Von Hippel-Lindau Tumor Suppressor Protein
"Von Hippel-Lindau Tumor Suppressor Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.
| Descriptor ID |
D051794
|
| MeSH Number(s) |
D08.811.464.938.750.875 D12.776.624.776.865
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Von Hippel-Lindau Tumor Suppressor Protein".
Below are MeSH descriptors whose meaning is more specific than "Von Hippel-Lindau Tumor Suppressor Protein".
This graph shows the total number of publications written about "Von Hippel-Lindau Tumor Suppressor Protein" by people in this website by year, and whether "Von Hippel-Lindau Tumor Suppressor Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Von Hippel-Lindau Tumor Suppressor Protein" by people in Profiles.
-
HIF1a-regulated glycolysis promotes activation-induced cell death and IFN-? induction in hypoxic T cells. Nat Commun. 2024 Oct 30; 15(1):9394.
-
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024 Oct; 25(10):1325-1336.
-
REST-dependent downregulation of von Hippel-Lindau tumor suppressor promotes autophagy in SHH-medulloblastoma. Sci Rep. 2024 06 12; 14(1):13596.
-
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Res. 2024 May 01; 30(9):1750-1757.
-
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. Nat Genet. 2024 May; 56(5):809-818.
-
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. J Clin Invest. 2024 Apr 15; 134(8).
-
Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease. Ophthalmology. 2024 May; 131(5):622-633.
-
Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 10 01; 129(19):2927-2940.
-
Developing a disease-specific annotation protocol for VHL gene curation using Hypothes.is. Database (Oxford). 2023 01 06; 2023.
-
Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. Clin Genitourin Cancer. 2023 04; 21(2):238-247.